news 2
Source: Medical News Today
Phase 3 clinical trial results shared in a press release suggest a new drug called lecanemab helps slow the cognitive decline rate in Alzheimer’s patients by 27% after 18 months of treatment.
Phase 3 clinical trial results shared in a press release suggest a new drug called lecanemab helps slow the cognitive decline rate in Alzheimer’s patients by 27% after 18 months of treatment.